Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Alterity Therapeutics Ltd. ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics Ltd. has announced that it received a notice from Point72 Associates, LLC, which was disclosed following the Australian Takeovers Panel Guidance Note 20 on Equity Derivatives. This disclosure involves the long equity derivative positions held by Point72 in Alterity, which could affect the company’s shares and American Depository Receipts. The transparency of such positions is essential as it may impact the market perception and valuation of Alterity’s securities.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. is a biopharmaceutical company focusing on the development of therapies for neurodegenerative diseases. The company is listed on both the Australian Securities Exchange (ASX) and NASDAQ, and it is engaged in creating novel treatments for diseases like Alzheimer’s and Parkinson’s.
YTD Price Performance: 0%
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $46.3M
See more insights into ATH stock on TipRanks’ Stock Analysis page.
